Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience

Frontiers in Medicine

Huan-Sheng Chen¹  Ning-Yi Hsia²  Chun-Ting Lai²  Wen-Chuan Wu²  Jane-Ming Lin³  Wen-Lu Chen³  Peng-Tai Tien⁴  Yi-Yu Tsai⁵  Cheng-Hsien Chang⁵  Chun-Ju Lin⁵  Henry Bair⁶ 

[1] An-Shin Dialysis Center, NephroCare Ltd., Fresenius Medical Care, Taichung, Taiwan;Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan;Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan;Department of Optometry, Asia University, Taichung, Taiwan;Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan;Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan;Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan;School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan;Department of Optometry, Asia University, Taichung, Taiwan;Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan;School of Medicine, Stanford University, Stanford, CA, United States;

关键词: diabetic macular edema;    intravitreal dexamethasone implant;    intravitreal ranibizumab;    ozurdex;    refractory diabetic macular edema;   

DOI  :  10.3389/fmed.2021.649979

来源: Frontiers

【 授权许可】

CC BY